Details for New Drug Application (NDA): 211367
✉ Email this page to a colleague
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.
Summary for 211367
Tradename: | SLYND |
Applicant: | Exeltis Usa Inc |
Ingredient: | drospirenone |
Patents: | 15 |
Suppliers and Packaging for NDA: 211367
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SLYND | drospirenone | TABLET;ORAL | 211367 | NDA | Exeltis USA, Inc. | 0642-7470 | 0642-7470-01 | 1 KIT in 1 CARTON (0642-7470-01) * 24 TABLET, FILM COATED in 1 BLISTER PACK * 4 TABLET, FILM COATED in 1 BLISTER PACK |
SLYND | drospirenone | TABLET;ORAL | 211367 | NDA | Exeltis USA, Inc. | 0642-7470 | 0642-7470-02 | 1 KIT in 1 CARTON (0642-7470-02) * 24 TABLET, FILM COATED in 1 BLISTER PACK * 4 TABLET, FILM COATED in 1 BLISTER PACK |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 4MG | ||||
Approval Date: | May 23, 2019 | TE: | AB | RLD: | Yes | ||||
Patent: | 10,179,140 | Patent Expiration: | Jun 28, 2031 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE | ||||||||
Patent: | 10,603,281 | Patent Expiration: | Jun 28, 2031 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE | ||||||||
Patent: | 10,849,857 | Patent Expiration: | Jun 28, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE |
Complete Access Available with Subscription